Form 4: Rhythm Pharmaceuticals Director Lynn Tetrault Reports New Equity Grants

Lynn A. Tetrault, a Director at Rhythm Pharmaceuticals, Inc., reported the acquisition of stock options and restricted stock units as part of her compensation.

Summary

• Lynn A. Tetrault, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), reported the acquisition of 7,037 stock options and 4,712 Restricted Stock Units (RSUs) on June 24, 2025.
• The stock options have an exercise price of $63.66 per share and an expiration date of June 23, 2035.
• Both the stock options and RSUs are scheduled to fully vest upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders in 2026, contingent on Ms. Tetrault's continued service.
• Each restricted stock unit represents a contingent right to receive one share of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The filing reports a standard equity grant to a director, which is a routine compensation event and generally viewed neutrally to slightly positive as it aligns insider interests with shareholders.

Positives

• The grant of equity, including stock options and restricted stock units, to Director Lynn A. Tetrault helps align her interests with those of the company's shareholders, incentivizing long-term performance.
• The equity grants are a standard component of director compensation, reflecting ongoing commitment to attracting and retaining qualified board members.

Negatives

• The future exercise of stock options and vesting of restricted stock units could lead to a slight dilution of existing shareholder equity, although this is a common aspect of equity compensation plans.

Risks

• The vesting of both stock options and restricted stock units is subject to the Reporting Person's continued service on the vesting date, meaning the benefits are contingent on her ongoing role as a director.

Future Outlook

The future outlook for the granted securities is tied to their vesting schedule, which is set to occur upon the earlier of June 24, 2026, or the day prior to the Issuer's 2026 annual meeting, provided the director continues her service.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation within the pharmaceutical industry, reflecting standard practices for incentivizing board members.

Related Party Transactions

• Grant of 7,037 stock options and 4,712 restricted stock units to Lynn A. Tetrault, a Director of Rhythm Pharmaceuticals, Inc., as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential future dilution from the exercise of options and vesting of RSUs, but also improved alignment of director's interests with company performance.
• Director: Increased equity stake and compensation, incentivizing continued service and performance.

Next Steps

• Vesting of the 7,037 stock options and 4,712 restricted stock units upon meeting the specified service and time conditions (earlier of June 24, 2026, or the day prior to the 2026 annual meeting).

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Grant, Director Compensation, Beneficial Ownership